ARVO 2017 is in the books and the conference was bigger and better than ever before. For a premier CRO in the field of ophthalmology, ARVO is a unique opportunity for networking and meeting new people in the industry. ARVO, unlike most conferences in the field, is a lengthy program, spanning over the course of six days with four of those days...Read More »
The field Ophthalmology has a substantial number of rare disease representation. Which of these diseases can fall under the definition of of a rare disease, and what can the field of research do to find cures? Below are examples of rare ophthalmic diseases and what the industry has done to treat them.
Retinoblastoma is a rare...Read More »
In the field of ophthalmology, contract research organizations strive towards a common goal to finding cures. Some circles of study focus on the pediatric aspect of medicine, finding cures for genetic or early onset disease indications that affect young children. In life, accidents happen, and we can only do what we can to protect our children,...Read More »
Trial Runners is preparing to hit the road for Conference season this year. The field of ophthalmology offers multipile options for industry thought leaders and presenters to network and share ideas in a forum setting.
The Clinical Trial Innovation Summit in Boston, MA will be an opportunity for Trial Runners to announce and unveil their new...Read More »
Ophthalmic findings, in an effort to finding cures sooner and serving the patients, attach imperative to be on the cutting edge. The future of ophthalmology lies in the utilization of stem cells to promote tissue growth or gene therapy to introduce a gene via a viral vector to the target tissue for the treatment of eye diseases. Stem cells and...Read More »
Timeline achievement is central to a successful clinical trial and pivotal to staying within budget. When approaching a project, a sponsor must address how a CRO approaches timelines. Trial Runners shares the sponsor’s commitment to timeline achievement, not just by meeting established timelines but by establishing the most aggressive in the... Read More »
Trial Runners, a full-service ophthalmology CRO, partners with pharmaceutical, biotech and device companies to bring treatments and cures to 1.3 million Americans who are legally blind. While so many patients are afflicted with this debilitating condition, the condition is wrought with misconceptions.
# 1 - Blind people can’t see.
The truth is...Read More »
The final outcome of any clinical trial – the ability to bring new treatments to market – depends on successful patient recruitment and retention despite the unique limitations and challenges of the trial, among other factors. When enrollment initiatives fail or patients discontinue participation before study completion, sponsor costs increase,...Read More »
As a premier ophthalmology CRO, our expertise does not fall short on just the field of ocular indications. Some afflictions of the eye constitute as a rare disease such as Friedrich's Ataxia and Alport Syndrome. Trial Runners has expanded its services to help the rare disease and orphan drug industry to bring comfort and hope to patients suffering...Read More »
Trial Runners is happy to announce that they will be attending the Clinical Trial Innovation Summit in Boston, MA this year. With increased opportunity in the industry for Trial Runners, they have in kind increased their conference visibility, and that means participation in other forefront conferences, summits and congresses in the field of...Read More »